ADMA Biologics, Inc. ADMA R2K

Healthcare · Biotechnology · United States

https://www.admabiologics.com

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Market & Price

Market Cap

$1.85B

Current Price

$7.98

High / Low (52W)

$21.87 / $7.88

Beta

0.82

Valuation

Stock P/E

11.74

Industry PE

23.65

Forward P/E

7.55

PEG Ratio

Book Value

$1.68

Price to Book

4.75

P/S

3.63

EV/EBITDA

202.94

Dividend Yield

Profitability & Returns

ROCE

34.21%

ROE

43.30%

ROA

21.99%

Profit Margin

32.43%

Op Margin

EPS (Latest Qtr)

$0.19

EPS (TTM)

$0.68

Balance Sheet & Liquidity

Debt/Equity

1.11

Quick Ratio

3.73

Current Ratio

6.95

Debt

$97.67B

Total Assets

$624.24M

Current Assets

$466.51M

Working Capital

$396.97M

Ownership

Promoter Holding

1.87%

Chg in Prom Hold

FII / Inst Holding

93.80%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$43.60B

Total Revenue (TTM)

$509.86M

EBITDA

$214.82M

Free Cash Flow

$58.35M

Operating Cash Flow

$128.32M

Shares Outstanding

231.77M

Gross Margin

61.27%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

49.05%

Profit 5Y

107.65%

Revenue (YoY)

15.90%

Earnings (YoY)

PROS

Strong return on equity of 43.3%.
Healthy ROCE of 34.2%.
Excellent profit margin of 32.4%.
Compounding revenue at 49.0% over 5 years.
Profit CAGR of 107.6% over 5 years.
Generates positive free cash flow.

CONS

Trading 63.5% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ADMA ADMA Biologics, Inc. R2K	7.98	11.74	$1.85B	-	34.21%	43.30%	49.05%	107.65%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.79M	10.28M	16.05M	17.83M	20.68M	29.10M	33.91M	41.09M	56.91M	60.12M	67.28M	81.88M	107.19M	119.84M	114.80M	121.98M	134.22M	139.16M	114.49M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	53.70M	54.76M	58.60M	50.35M	33.74M
Gross Profit	381.10K	583.53K	559.50K	498.25K	593.48K	523.62K	739.63K	857.47K	927.50K	1.20M	1.01M	-934.62K	-6.56M	-	-	-	-	-	-	-	-	-	-	-1.72M	-1.00M	385.34K	3.66M	7.77M	9.66M	16.51M	16.69M	24.65M	39.11M	57.45M	59.66M	61.10M	67.23M	75.63M	88.82M	80.75M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26.22M	24.43M	24.61M	26.07M	30.46M
Operating Income	-2.53M	-5.68M	-3.59M	-3.04M	-3.20M	-3.52M	-4.66M	-4.16M	-5.49M	-3.74M	-5.94M	-8.40M	-14.43M	-16.53M	-13.42M	-13.79M	-16.55M	-13.21M	-11.34M	-9.05M	-16.77M	-17.12M	-13.80M	-15.16M	-15.58M	-14.44M	-14.82M	-9.17M	-9.32M	-813.00K	-473.00K	8.69M	21.82M	39.20M	39.64M	34.88M	42.80M	51.01M	62.75M	50.29M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	37.39M	43.99M	51.21M	65.27M	61.07M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.98M	1.83M	1.68M	1.63M	2.10M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	33.45M	40.10M	47.52M	61.59M	57.13M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.55M	5.88M	11.09M	12.22M	11.80M
Net Income	-2.69M	-5.90M	-3.96M	-3.38M	-3.61M	-4.68M	-5.10M	-4.61M	-6.01M	-4.33M	-6.54M	-9.04M	-15.20M	-17.82M	-14.75M	-15.14M	-18.04M	-13.07M	-13.21M	-11.44M	-19.25M	-20.18M	-16.92M	-18.38M	-18.91M	-17.71M	-25.01M	-13.76M	-14.90M	-6.79M	-6.37M	2.56M	17.81M	32.06M	35.91M	26.90M	34.22M	36.43M	49.38M	45.33M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.23	-0.19	-0.16	-0.15	-0.13	-0.13	-0.07	-0.08	-0.03	-0.03	0.01	0.08	0.13	0.15	0.11	0.14	0.15	0.20	0.19
R&D Expense	1.41M	4.33M	1.78M	1.48M	1.40M	1.51M	2.11M	2.03M	3.40M	1.68M	1.19M	1.36M	1.81M	965.57K	1.04M	1.00M	917.30K	870.63K	516.99K	491.40K	1.53M	1.66M	1.71M	987.65K	1.16M	770.56K	624.11K	873.39K	1.04M	855.00K	1.40M	596.00K	450.00K	560.00K	412.00K	826.00K	1.03M	1.53M	-	2.60M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	42.22M	-	154.08M	258.21M	426.45M	510.17M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	118.81M	169.27M	206.90M	217.41M
Gross Profit	553.47K	449.06K	1.04M	2.17M	2.87M	4.30M	-6.40M	-25.21M	-	-19.07M	-	35.27M	88.94M	219.55M	292.76M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	74.63M	67.31M	80.57M	101.32M
Operating Income	-4.62M	-7.91M	-15.04M	-16.02M	-15.51M	-17.33M	-39.31M	-60.29M	-41.42M	-64.91M	-	-39.37M	21.63M	138.98M	191.44M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-39.51M	5.12M	147.69M	197.86M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	19.28M	25.03M	13.93M	7.11M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-65.90M	-28.24M	125.71M	182.66M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	0	0	-71.96M	35.73M
Net Income	-5.90M	-7.30M	-15.53M	-16.81M	-17.97M	-19.52M	-43.76M	-65.74M	-48.28M	-75.75M	-	-65.90M	-28.24M	197.67M	146.93M
Diluted EPS	-	-	-	-	-	-	-	-	-	-0.88	-0.51	-0.33	-0.13	0.81	-
R&D Expense	646.76K	3.47M	9.30M	9.52M	7.02M	7.69M	5.57M	3.93M	2.34M	5.91M	3.65M	3.61M	3.30M	1.81M	4.76M

Compounded Sales Growth

5 Years:	49.05%
1 Year:	15.90%

Compounded Profit Growth

5 Years:	107.65%
1 Year:	-

Stock Price Performance

1 Year:	-59.78%
6 Months:	-58.46%
3 Months:	-48.75%
1 Month:	-24.72%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	2.93M	15.56M	31.98M	27.02M	23.71M	23.69M	108.02M	88.88M	127.09M	207.67M	-	348.46M	329.18M	488.68M	624.24M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	270.40M	257.01M	331.41M	466.51M
Cash & Equivalents	228.97K	87.77K	12.54M	26.15M	17.20M	10.44M	9.91M	43.11M	26.75M	26.75M	55.92M	-	86.52M	51.35M	103.15M	87.63M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	163.28M	172.91M	170.24M	206.47M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	15.51M	27.42M	50.00M	158.43M
Total Liabilities	-	2.54M	6.13M	10.41M	21.01M	22.89M	28.14M	67.69M	69.11M	100.90M	119.42M	-	196.49M	193.98M	139.66M	146.92M
Current Liabilities	-	2.30M	1.82M	3.66M	4.20M	4.22M	11.22M	9.44M	9.63M	14.03M	19.95M	-	39.27M	49.81M	55.54M	69.54M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	142.83M	130.59M	72.34M	69.33M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	154.44M	141.42M	82.12M	79.89M
Total Equity	-3.93M	385.82K	9.42M	21.57M	6.01M	820.97K	-4.46M	40.33M	19.77M	26.19M	88.25M	-	151.97M	135.21M	349.02M	477.32M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	221.82M	226.06M	236.62M	239.79M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-1.43M	-6.90M	-10.89M	-14.70M	-15.42M	-18.27M	-37.27M	-62.68M	-76.19M	-102.00M	-	-59.51M	8.80M	118.67M	50.40M
Investing Cash Flow	-270	-118.85K	-3.13M	-4.04M	-1.74M	904.58K	15.21M	-2.10M	-3.81M	-12.72M	-	-13.91M	-4.98M	-8.57M	-21.89M
Financing Cash Flow	1.29M	19.47M	27.63M	9.80M	10.40M	16.84M	60.75M	42.92M	80.00M	143.90M	-	108.85M	-38.99M	-58.30M	-44.02M
Capital Expenditure	-270	-118.85K	-196.63K	-2.32M	-26.07K	-73.41K	-2.68M	-2.10M	-3.81M	-12.73M	-	-13.91M	-4.98M	-8.57M	-22.89M
Free Cash Flow	-1.43M	-7.02M	-11.08M	-17.03M	-15.44M	-18.34M	-39.95M	-64.77M	-80.01M	-114.73M	-	-73.42M	3.82M	110.10M	27.50M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	35.43M	-35.17M	51.80M	-15.52M
Share Buybacks	0	150.00K	-	-	-	-	-	-	-	-	-	-	0	0	31.94M

Ratios (Annual)

Figures in %.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-45.2%	-	22.9%	34.4%	51.5%	57.4%
Operating Margin %	-	-	-	-	-	-	-	-	-	-153.8%	-	-25.5%	8.4%	32.6%	37.5%
Net Margin %	-	-	-	-	-	-	-	-	-	-179.4%	-	-42.8%	-10.9%	46.4%	28.8%
ROE %	-1,530.1%	-77.5%	-72.0%	-279.8%	-2,188.9%	437.8%	-108.5%	-332.5%	-184.3%	-85.8%	-	-43.4%	-20.9%	56.6%	30.8%
ROCE %	-740.6%	-57.6%	-53.1%	-70.2%	-79.6%	-139.1%	-39.9%	-76.1%	-36.6%	-34.6%	-	-12.7%	7.7%	32.1%	34.5%

Shareholding Pattern

Insiders

1.87%

Institutions

93.80%

Public Float

95.59%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	15.89%	36.83M	$293.91M
2	State Street Corporation	6.08%	14.08M	$112.39M
3	Capital Research Global Investors	4.83%	11.19M	$89.31M
4	Vanguard Capital Management LLC	4.45%	10.31M	$82.25M
5	Vanguard Portfolio Management LLC	3.83%	8.87M	$70.77M
6	Nuveen, LLC	2.63%	6.10M	$48.66M
7	Geode Capital Management, LLC	2.51%	5.82M	$46.48M
8	Citadel Advisors Llc	2.51%	5.81M	$46.37M
9	Dimensional Fund Advisors LP	2.16%	5.01M	$39.94M
10	American Century Companies Inc	2.07%	4.79M	$38.22M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ADMA

No recent headlines available.

ADMA · Healthcare